Neural correlates of rapid antidepressant response to ketamine in bipolar disorder
Allison C. Nugent, Nancy Diazgranados, Paul J. Carlson, Lobna Ibrahim, David A. Luckenbaugh, Nancy E. Brutsché, Peter Herscovitch, Wayne C. Drevets, Carlos A. Zarate
Bipolar Disorders September 18, 2013 DOI: 10.1111/bdi.12118 via OpenAlex
Summary
In people with bipolar disorder who are depressed, a single ketamine infusion alters brain glucose metabolism in regions linked to mood disorders. Those who improved most showed the largest metabolic increase in the right ventral striatum. Ketamine also lowered metabolism in the left hippocampus compared with placebo. Higher baseline activity in the subgenual anterior cingulate cortex predicted a stronger antidepressant response to ketamine. These metabolic changes may help explain how ketamine works.
Study at a glance
| Characteristics | Double-blind, randomized, cross-over study Peer reviewed |
|---|---|
| Sample size | 21 |
| Population | Subjects with bipolar disorder currently in a depressed state |
| Interventions | Ketamine Placebo |
| Topics | Depression Ketamine |
| Keywords | Placebo Antidepressant Anterior cingulate cortex |
| Citations | 86 |
| Key finding | Higher activity in the subgenual anterior cingulate cortex after placebo infusion predicted antidepressant response to ketamine. |
Abstract
OBJECTIVES: Ketamine, an N-methyl d-aspartate (NMDA) antagonist, has rapid antidepressant effects in depressed subjects with bipolar disorder (BD). Evidence supports a role for the glutamatergic system in the pathophysiology of BD. This double-blind, randomized, cross-over study sought to determine cerebral metabolic correlates of antidepressant response to ketamine. METHODS: Twenty-one subjects with BD currently in a depressed state underwent [(18) F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging after receiving a placebo infusion as well as after receiving a ketamine infusion. Metabolism was compared between ketamine and placebo infusions, and correlated with clinical response. Regional metabolic rate of glucose (rMRGlu) in regions of interest (ROIs) and Montgomery-Åsberg Depression Rating Scale (MADRS) scores were the main outcome measures. RESULTS: The study found that change in metabolism between sessions was significantly correlated with percentage change in MADRS scores in the right ventral striatum; subjects who showed the greatest improvement had the largest metabolic increase after ketamine infusion compared to placebo. In a voxel-wise analysis, subjects with BD had significantly lower glucose metabolism in the left hippocampus following the ketamine infusion than following the placebo infusion. In addition, metabolism in the subgenual anterior cingulate cortex (ACC) following the placebo infusion was positively correlated with percentage improvement in MADRS score following the ketamine infusion. CONCLUSIONS: Taken together, the results suggest that higher activity in the subgenual ACC may predict antidepressant response to ketamine. Ketamine administration altered glucose metabolism in areas known to be involved in mood disorders; these alterations may partially underlie ketamine's mechanism of action.